gemcitabine has been researched along with eflornithine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Von Hoff, DD | 1 |
| Altomare, DA; Copik, AJ; Gitto, SB; Hogan, FC; Oyer, JL; Pandey, V; Phanstiel, O | 1 |
2 other study(ies) available for gemcitabine and eflornithine
| Article | Year |
|---|---|
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Eflornithine; Gemcitabine; Humans; Mitoguazone; Neoplasms; Research Design | 1998 |
Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Transport; Biosynthetic Pathways; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Eflornithine; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Pancreas; Pancreatic Neoplasms; Polyamines; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |